Glaukos. has filed a patent for a micro-device designed for corneal cross-linking treatment. The device includes a body with an outer and inner portion, an illumination system with micro-LEDs to direct photoactivating light to the cornea, and an optical fiber to reflect light from a source to the micro-optical element. GlobalData’s report on Glaukos gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Glaukos, Customized implants was a key innovation area identified from patents. Glaukos's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Micro-device for corneal cross-linking treatment
A newly filed patent (Publication Number: US20240009031A1) describes a micro-device designed for corneal cross-linking treatment. The device includes a body with an outer portion and an inner portion, forming a chamber over the cornea of the eye. An illumination system with micro-light emitting diodes (micro-LEDs) directs photoactivating light to the cornea, generating cross-linking activity with a cross-linking agent. The device is made from an oxygen-permeable material, allowing oxygen to enter the chamber, and includes micro-channels for oxygen delivery. Additionally, a controller can activate subsets of micro-LEDs to produce specific light patterns for treatment.
Furthermore, the micro-device features a flexible tube for oxygen and cross-linking agent delivery, side channels for oxygen flow, and vents for oxygen exit. The micro-LEDs are in optical communication with a micro-lens array for focused light delivery, and a reflective coating ensures efficient light reflection within the chamber. The device can produce circular or annular light patterns, with some micro-LEDs activated at higher intensities for customized treatment. Additionally, a spatial light modulator and diffractive optical element can generate specific light patterns for treatment. Overall, the micro-device offers a sophisticated and precise method for corneal cross-linking treatment, with various features to enhance treatment efficacy and customization based on patient needs.
To know more about GlobalData’s detailed insights on Glaukos, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.